|
Last Updated: Nov 18, 2006 - 12:32:53 PM |
Latest Research
:
Cancer
:
Blood
Medication errors affect children's leukemia treatment
Almost one in five children treated for acute lymphoblastic leukemia (ALL) does not receive the appropriate chemotherapy regimen due to medication errors, according to a new study. Published in the September 15, 2006 issue of CANCER, a peer-reviewed journal of the American Cancer Society, the study reveals that 10 percent of chemotherapeutic medications for outpatients were prescribed or administered incorrectly. Though most were of little clinical significance, in some patients the errors may have put the patients at risk either for relapse or for overdose-related complications.
Aug 14, 2006 - 11:34:00 AM
Latest Research
:
Cancer
:
Blood
JAK-STAT pathway inhibitors are likely to be effective against some leukemias
New research indicates that drugs that target a cell growth pathway known as the JAK-STAT pathway are likely to be effective against certain chronic leukemias. Researchers recently discovered that a mutation in the JAK2 gene is responsible for the majority of cases of three rare kinds of chronic leukemia, all of which are resistant to the leukemia drug Gleevec. The new study identifies a second mutation in the same pathway that can also cause the disease, leading researchers to think that drugs targeting JAK-STAT signaling should be effective against leukemias caused by either mutation.
Jul 24, 2006 - 11:28:00 PM
Latest Research
:
Cancer
:
Blood
HO-1 in sickle cell disease
Researchers have unexpectedly shown that sickle cell-associated kidney injury may be reduced by inhibiting the enzyme activity of a protein that commonly confers protection in other diseased states. The paper by Juncos et al., 'Anomalous renal effects of tin protoporphyrin in a murine model of sickle cell disease,' appears in the July issue of The American Journal of Pathology.
Jul 19, 2006 - 3:33:00 AM
Latest Research
:
Cancer
:
Blood
Dasatinib treats resistant cases of CML
An experimental therapy that battles drug resistance in Chronic Myeloid Leukemia (CML) has proved "extremely effective" in fighting cancer, giving patients for whom all conventional therapies have failed another option, researchers at UCLA's Jonsson Cancer Center reported.
Jun 15, 2006 - 11:29:00 AM
Latest Research
:
Cancer
:
Blood
HBZ protein enhance ability of HTLV-1 to establish persistent infection
A protein made by a cancer-causing virus using an unusual gene enables that virus to infect immune cells and persist in the host, new research shows. The study examines the function of a protein called HBZ, which is made by the human T cell leukemia virus type 1 (HTLV-1), a retrovirus and a distant cousin to HIV, the cause of AIDS.
Jun 12, 2006 - 7:56:00 PM
Latest Research
:
Cancer
:
Blood
Gene expression signature for Burkitt lymphoma identified
An international research study involving the University of Nebraska Medical Center, the National Cancer Institute and 10 other institutions has successfully identified the gene expression signature for Burkitt lymphoma. The discovery, which is reported in the June 8 edition of The New England of Medicine, will allow physicians to better diagnose and treat Burkitt lymphoma and better distinguish it from another more common form of malignant lymphoma. Burkitt lymphoma is a rare aggressive B cell lymphoma that accounts for 30 to 50 percent of lymphomas in children but only 1 to 2 percent of lymphomas in adults. Burkitt lymphoma is rapidly fatal if untreated, but it is curable with intensive therapy. Burkitt lymphoma features a high degree of proliferation of the malignant cells and deregulation of the c-myc gene, which is characteristic of Burkitt lymphoma. The distinction between Burkitt lymphoma and diffuse large B cell lymphoma (DLBCL), the most common form of non-Hodgkin�s lymphoma in adults, is critical, because the management of these two diseases differs. About 300 new cases of Burkitt lymphoma, typically in children, are diagnosed in the U.S. each year.
Jun 10, 2006 - 1:47:00 PM
Latest Research
:
Cancer
:
Blood
Bcr-Abl mutation and the loss of Arf genes triggers an aggressive form of ALL
Investigators at St. Jude Children's Research Hospital have used mouse models to determine why some forms of acute lymphoblastic leukemia (ALL) are extremely aggressive and resist a drug that is effective in treating a different type of leukemia. The investigators found that the combination of a mutation called Bcr-Abl and the loss of both copies of the tumor suppressor gene Arf in bone marrow cells triggers an aggressive form of ALL. Inactivation of both Arf genes facilitated the multiplication of leukemic cells that did not respond to the drug imatinib (Gleevec�). Imatinib is already successfully used to treat chronic myelogenous leukemia (CML), another blood cell cancer caused by the Bcr-Abl mutation.
Apr 20, 2006 - 4:46:00 PM
Latest Research
:
Cancer
:
Blood
New simple and inexpensive test for follow-up of acute lymphoblastic leukemia (ALL)
Investigators at St. Jude Children's Research Hospital have developed a relatively simple and inexpensive test that identifies children with acute lymphoblastic leukemia (ALL) who have responded well enough to their first round of chemotherapy that they might be successfully treated with a much less aggressive follow-up treatment.
Mar 30, 2006 - 3:14:00 PM
Latest Research
:
Cancer
:
Blood
miRNAs abnormal signalling may lead to platelet-related leukemias
Scientists have identified a handful of microRNAs (miRNAs) that appear to play a significant role in the development of platelets � blood cells critical to the body�s ability to form clots following an injury. They also say some of these same miRNAs, when acting abnormally, may contribute to certain forms of leukemia.
Mar 16, 2006 - 10:01:00 PM
Latest Research
:
Cancer
:
Blood
DNA itself can act as a mutagen
When otherwise normal DNA adopts an unusual shape called Z-DNA, it can lead to the kind of genetic instability associated with cancers such as leukemia and lymphoma, according to a study by researchers at The University of Texas M. D. Anderson Cancer Center.
Feb 12, 2006 - 6:01:00 PM
Latest Research
:
Cancer
:
Blood
New Drug VX-680 May Overcome Deadly Leukemia Mutation
HHMI researchers have discovered how a new generation of drugs thwarts a deadly mutation that causes chronic myelogenous leukemia (CML).
Jan 20, 2006 - 10:08:00 PM
Latest Research
:
Cancer
:
Blood
Garden insecticides may increase leukaemia risk
Household insecticides may increase the risk of leukemia, says a new study, reinforcing the theory that pesticide exposure may play a role in childhood acute leukaemia.
Jan 18, 2006 - 12:22:00 AM
Latest Research
:
Cancer
:
Blood
Childhood leukaemia linked with household insecticides
Household insecticides may increase the risk of childhood leukaemia, suggests French research in Occupational and Environmental Medicine .
Jan 17, 2006 - 6:54:00 PM
Latest Research
:
Cancer
:
Blood
The cure rate for ALL could reach 90 percent
The cure rate for the once almost universally fatal childhood cancer acute lymphoblastic leukemia (ALL) could reach 90 percent in the near future, thanks to improvements in diagnosis and treatment over the past four decades, according to investigators at St. Jude Children's Research Hospital.
Jan 12, 2006 - 5:21:00 AM
Latest Research
:
Cancer
:
Blood
:
Non-Hodgkin's Lymphoma
PCBs, Furans May Factor in Risk of Non-Hodgkin Lymphoma
Scientists have found some additional evidence that environmental exposure to polychlorinated biphenyls (PCBs) may be associated with non-Hodgkin lymphoma, according to a study published in the December 1 issue of Cancer Research. By comparing blood levels of PCBs in 100 pairs of healthy volunteers and non-Hodgkin lymphoma patients, Anneclaire De Roos, Ph.D., assistant professor of epidemiology, Fred Hutchinson Cancer Research Center, and colleagues determined that high levels of three specific molecular forms of PCBs are linked to an increased risk of developing cancer that starts in patients� lymph tissue.
Dec 2, 2005 - 8:03:00 PM
Latest Research
:
Cancer
:
Blood
Test Vaccine Effective for Follicular Lymphoma
A team of researchers has demonstrated the clinical efficacy and benefits of a vaccine for a type of blood cancer, follicular lymphoma, amongst first time relapse patients. Specialists from two University of Navarre centres � the University Hospital and the Research Centre for Applied Medicine (CIMA) - have worked jointly since 2001 on the research.
Nov 11, 2005 - 12:58:00 AM
Latest Research
:
Cancer
:
Blood
Treatment advances for follicular lymphoma have reduced deaths by 70%
New treatment advances for patients with follicular lymphoma, previously considered an incurable cancer, have reduced deaths in the first four years by 70 percent. A newly published study recommends that doctors carefully choose their patients' initial therapies because there are significant differences in overall survival rates, according to researchers at the University of Rochester Medical Center's James P. Wilmot Cancer Center.
Oct 21, 2005 - 11:22:00 PM
Latest Research
:
Cancer
:
Blood
Risk of Lymphoma Higher Among People With Family History of Hematopoietic Malignancy
A new study has confirmed the association between family history of hematopoietic malignancy--cancers of the blood or bone marrow, such as leukemia and lymphoma--and the most common types of lymphoma.
Oct 5, 2005 - 4:17:00 AM
Latest Research
:
Cancer
:
Blood
New blood transplant method stops fatal side effect
Findings published in the Sept. 29 issue of the New England Journal of Medicine suggest that the new therapy pioneered at Stanford University School of Medicine has paid off for lymphoma and leukemia patients. Holmes became the 40th person to undergo this procedure after Stanford researchers had shown that it could boost the relative levels of regulatory T cells in the immune system of mice - an effect that turned out to be beneficial before undergoing a hematopoietic (blood) stem cell transplantation, a common treatment for blood cancers.
Sep 29, 2005 - 8:35:00 PM
Latest Research
:
Cancer
:
Blood
MicroRNA genes are involved in CLL development
A new and unusual class of genes plays an important role in the development of chronic lymphocytic leukemia (CLL), according to new research here. At the same time, these genes may provide a new form of therapy for the disease.
Sep 13, 2005 - 4:52:00 AM
Latest Research
:
Cancer
:
Blood
:
Non-Hodgkin's Lymphoma
Tositumomab Brings New Hope for Refractory Non-Hodgkin's Lymphoma
Health Canada has approved a new treatment that could offer hope for those who suffer from what is considered an incurable form of non-Hodgkin's lymphoma (NHL) and who have failed on, or relapsed following, other treatments. Health Canada approved Bexxar(TM) (tositumomab and iodine I 131 tositumomab) therapy for the treatment of patients with CD20 positive relapsed or refractory, low grade, follicular, or transformed non-Hodgkin's lymphoma, including patients with rituximab- refractory NHL.
Sep 10, 2005 - 11:02:00 PM
Latest Research
:
Cancer
:
Blood
AMD-3100 May Help Cancer Patients in Need of Stem Cell Transplants
A new drug may help cancer patients mobilize the cells necessary to restore their blood-forming system after high-dose chemotherapy, according to results from a clinical trial at the Kimmel Cancer Center at Thomas Jefferson University Hospital in Philadelphia and at other centers across the nation.
Sep 9, 2005 - 3:54:00 PM
Latest Research
:
Cancer
:
Blood
:
Multiple Myeloma
Lenalidomide & dexamethasone combination shows promise for multiple myeloma treatment
Mayo Clinic Cancer Center investigators report that combination therapy with lenalidomide (RevlimidTM) and dexamethasone (combination is called Rev/Dex) looks like a breakthrough treatment for multiple myeloma. Results of a Phase II clinical trial were published online Aug. 23 in Blood.
Sep 4, 2005 - 7:16:00 AM
Latest Research
:
Cancer
:
Blood
Viral protein vFLIP K13 of HHV8 appear to cause lymphoma
A protein previously thought to merely hinder the activity of a key cellular protein linked to cancer cell death, now appears to mimic the cellular signaling of that protein; potentially leading to the development of lymphoma. The findings, published in the Aug. 22 online edition of Proceedings of the National Academy of Sciences (PNAS), demonstrate that a viral protein associated with human herpesvirus 8, or HHV8, may help to cause lymphoma by activating a key pathway involved in the production of lymphocytes, a common cell type found in lymphoid tissue that divide over and over and eventually develop into lymphoma.
Aug 23, 2005 - 8:22:00 PM
Latest Research
:
Cancer
:
Blood
:
Non-Hodgkin's Lymphoma
People who drink alcohol have a lower risk of non-Hodgkin's lymphoma (NHL)
People who drink alcohol have a lower risk of non-Hodgkin's lymphoma (NHL) than non-drinkers, researchers at Yale's Department of Epidemiology and Public Health (EPH) write in an article published in Lancet Oncology.
Aug 15, 2005 - 8:26:00 PM
Latest Research
:
Cancer
:
Blood
REVLIMID gets Priority Review Status for the Treatment of Myelodysplastic Syndromes
Celgene Corporation announced that the U.S. Food and Drug Administration (FDA) has granted a Priority Review designation to its New Drug Application (NDA) for REVLIMID with a Prescription Drug User Fee Act (PDUFA) date by October 7, 2005. The Company is seeking approval to market REVLIMID as a targeted treatment for transfusion-dependent patients with low- and intermediate-risk myelodysplastic syndromes (MDS) with deletion 5q chromosomal abnormality.
Jun 21, 2005 - 9:25:00 PM
Latest Research
:
Cancer
:
Blood
VX-680 : An Aurora Kinase Inhibitor Enters an Additional Phase I Study for its Use in Hematologic Cancers
Merck & Co, Inc and Vertex Pharmaceuticals Incorporated announced the initiation of an additional Phase I clinical study with VX-680, a small molecule inhibitor of Aurora kinases. The two-part, open-label, dose escalation study is designed to evaluate the safety and tolerability of VX-680 when administered over a five-day treatment cycle in patients with hematologic cancers.
Jun 20, 2005 - 10:52:00 AM
Latest Research
:
Cancer
:
Blood
Genes linked to treatment resistance in leukemia
Today, the most common childhood cancer is cured in about 80 percent of patients; only forty years ago, this number was closer to five percent. In efforts to further increase the survival rate, researchers from St. Jude Children's Research Hospital, the University of Tennessee, and the University of Chicago studied how an individual's genetics might play a role in the effectiveness of chemotherapy drugs. Their findings will be published in the June 15, 2005, issue of Blood, the official journal of the American Society of Hematology.
Jun 4, 2005 - 2:07:00 AM
Latest Research
:
Cancer
:
Blood
:
Multiple Myeloma
Novel combination overcomes drug-resistant myeloma
A novel strategy devised by Dana-Farber Cancer Institute scientists has proved highly effective in killing drug-resistant multiple myeloma cells in the laboratory and could open a new form of attack on the deadly blood cancer, they report.
Jun 3, 2005 - 4:51:00 PM
Latest Research
:
Cancer
:
Blood
Possible link between leukaemia and overhead power lines
Children living close to high voltage overhead power lines at birth may be at an increased risk of leukaemia, finds a large study in this week's BMJ.
Jun 3, 2005 - 4:47:00 PM
|
